ES2540151A1 - Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico - Google Patents

Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico Download PDF

Info

Publication number
ES2540151A1
ES2540151A1 ES201300963A ES201300963A ES2540151A1 ES 2540151 A1 ES2540151 A1 ES 2540151A1 ES 201300963 A ES201300963 A ES 201300963A ES 201300963 A ES201300963 A ES 201300963A ES 2540151 A1 ES2540151 A1 ES 2540151A1
Authority
ES
Spain
Prior art keywords
tramadol
ibuprofen
pharmaceutical composition
translation
machine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201300963A
Other languages
English (en)
Other versions
ES2540151B1 (es
Inventor
Fernando Martínez-Alzamora
José Miguel RIZO MARTÍNEZ
Antonia Gómez Calvo
Nuria Sanz Menéndez
Ángel Muñoz Ruiz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farmalider SA
Original Assignee
Farmalider SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmalider SA filed Critical Farmalider SA
Priority to ES201300963A priority Critical patent/ES2540151B1/es
Priority to MX2014012158A priority patent/MX355770B/es
Priority to BR102014025307-6A priority patent/BR102014025307B1/pt
Priority to ES14380031.6T priority patent/ES2685023T3/es
Priority to HUE14380031A priority patent/HUE040093T2/hu
Priority to PT14380031T priority patent/PT2862565T/pt
Priority to DK14380031.6T priority patent/DK2862565T3/en
Priority to PL14380031T priority patent/PL2862565T3/pl
Priority to US14/511,321 priority patent/US10292953B2/en
Priority to RU2014140885A priority patent/RU2694369C2/ru
Priority to ARP140103790A priority patent/AR097997A1/es
Priority to EP14380031.6A priority patent/EP2862565B1/en
Publication of ES2540151A1 publication Critical patent/ES2540151A1/es
Application granted granted Critical
Publication of ES2540151B1 publication Critical patent/ES2540151B1/es
Priority to HRP20181282TT priority patent/HRP20181282T1/hr
Priority to CY181100867T priority patent/CY1120642T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico. La presente invención se refiere a una composición farmacéutica de ibuprofeno y tramadol para uso oftálmico. Dicha composición resulta eficaz y segura para el tratamiento de la inflamación y/o el dolor ocular asociados a diversas enfermedades o estados patológicos que afectan a la zona ocular. En particular, la composición oftálmica de la invención está indicada, por ejemplo, para el tratamiento del dolor y/o la inflamación tras cirugía ocular.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
ES201300963A 2013-10-11 2013-10-11 Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico Active ES2540151B1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ES201300963A ES2540151B1 (es) 2013-10-11 2013-10-11 Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
MX2014012158A MX355770B (es) 2013-10-11 2014-10-08 Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico.
EP14380031.6A EP2862565B1 (en) 2013-10-11 2014-10-10 Pharmaceutical composition of ibuprofen and tramadol for ophthalmological use
HUE14380031A HUE040093T2 (hu) 2013-10-11 2014-10-10 Ibuprofén és tramadol gyógyászati kompozíciója szemgyógyászati alkalmazásra
PT14380031T PT2862565T (pt) 2013-10-11 2014-10-10 Composição farmacêutica de ibuprofeno e tramadol para utilização oftalmológica
DK14380031.6T DK2862565T3 (en) 2013-10-11 2014-10-10 Pharmaceutical composition of ibuprofen and tramadol for ophthalmic use
PL14380031T PL2862565T3 (pl) 2013-10-11 2014-10-10 Farmaceutyczna kompozycja ibuprofenu i tramadolu do zastosowania w okulistyce
US14/511,321 US10292953B2 (en) 2013-10-11 2014-10-10 Pharmaceutical composition of ibuprofen and tramadol for ophthalmic use
BR102014025307-6A BR102014025307B1 (pt) 2013-10-11 2014-10-10 Composição farmacêutica de ibuprofeno e tramadol para uso oftálmico
ARP140103790A AR097997A1 (es) 2013-10-11 2014-10-10 Composición farmaceutica de ibuprofeno y tramadol para uso oftálmico
ES14380031.6T ES2685023T3 (es) 2013-10-11 2014-10-10 Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
RU2014140885A RU2694369C2 (ru) 2013-10-11 2014-10-10 Фармацевтическая композиция ибупрофена и трамадола для офтальмологического применения
HRP20181282TT HRP20181282T1 (hr) 2013-10-11 2018-08-03 Farmaceutski pripravak ibuprofena i tramadola, namijenjen očnoj upotrebi
CY181100867T CY1120642T1 (el) 2013-10-11 2018-08-17 Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201300963A ES2540151B1 (es) 2013-10-11 2013-10-11 Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico

Publications (2)

Publication Number Publication Date
ES2540151A1 true ES2540151A1 (es) 2015-07-08
ES2540151B1 ES2540151B1 (es) 2016-02-29

Family

ID=51868157

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201300963A Active ES2540151B1 (es) 2013-10-11 2013-10-11 Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
ES14380031.6T Active ES2685023T3 (es) 2013-10-11 2014-10-10 Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14380031.6T Active ES2685023T3 (es) 2013-10-11 2014-10-10 Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico

Country Status (13)

Country Link
US (1) US10292953B2 (es)
EP (1) EP2862565B1 (es)
AR (1) AR097997A1 (es)
BR (1) BR102014025307B1 (es)
CY (1) CY1120642T1 (es)
DK (1) DK2862565T3 (es)
ES (2) ES2540151B1 (es)
HR (1) HRP20181282T1 (es)
HU (1) HUE040093T2 (es)
MX (1) MX355770B (es)
PL (1) PL2862565T3 (es)
PT (1) PT2862565T (es)
RU (1) RU2694369C2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2604816A1 (es) * 2015-09-09 2017-03-09 Farmalider, S.A. Composición farmacéutica de tramadol para uso oftálmico

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUB20153104A1 (it) * 2015-08-13 2017-02-13 Sooft Italia S P A Contrada Molino 17 68333 Montegiorgio Fm Composizione ed uso di collirio a base di inositolo per migliorare l'accomodazione visiva dei pazienti
AR102172A1 (es) * 2015-10-05 2017-02-08 Química Luar S R L Una composición farmacéutica bactericida y virucida
RU2624901C2 (ru) * 2015-10-05 2017-07-07 Елизавета Геннадьевна Полунина Средство для аппликационной анестезии с антисептическими, оптикокератопротективными свойствами и способ его применения в офтальмологии
KR20190061047A (ko) 2016-09-30 2019-06-04 마티 테라퓨틱스 인코포레이티드 안과 약제의 서방성 제형 및 그 용도
FI3996699T3 (fi) * 2019-07-09 2023-08-01 Farmalider Sa Ibuprofeenin ja tramadolin yhdistelmä kivun lievitykseen
WO2024010040A1 (ja) * 2022-07-06 2024-01-11 ロート製薬株式会社 眼科組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2356762A1 (es) * 2009-09-04 2011-04-13 Farmalider S.A. Composicion farmaceutica de ibuprofeno, tramadol y un aminoacido basico, procedimiento para su preparacion y utilizacion de la misma.
CN102058581A (zh) * 2010-11-30 2011-05-18 广东宏盈科技有限公司 一种眼科外用非甾体抗炎药
WO2013124498A1 (es) * 2012-02-22 2013-08-29 Farmauder, S.A. Composición farmacéutica de ibuprofeno y tramadol para inyección
WO2013150277A1 (en) * 2012-04-05 2013-10-10 Anant Sharma Ophthalmic therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB971700A (en) 1961-02-02 1964-09-30 Boots Pure Drug Co Ltd Anti-Inflammatory Agents
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
GB1497044A (en) 1974-03-07 1978-01-05 Prodotti Antibiotici Spa Salts of phenyl-alkanoic acids
AU661723B2 (en) * 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
CN1513442A (zh) * 2003-06-26 2004-07-21 昆明市延安医院 精氨酸-布洛芬混合物的制法和用途
SI1888033T1 (sl) * 2005-06-09 2014-06-30 Meda Ab Postopek in sestavek za zdravljenje vnetnih motenj
CN101563074B (zh) * 2006-10-20 2012-11-07 麦克内尔-Ppc股份有限公司 乙酰氨基酚/布洛芬组合
BRPI0810773A2 (pt) * 2007-04-30 2014-10-07 Adolor Corp Composição farmacêutica, métodos para tratar dor em um mamífero, para tratar depressão em um mamífero, para tratar um distúrbio em um paciente, para fabricar um composto, e para inibir a captação de norepinefrina, composto, e, uso de uma composição.
EP3799866A1 (en) * 2011-04-05 2021-04-07 Optosolve Research & Development Ltd Ophthalmic treatments comprising tramadol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2356762A1 (es) * 2009-09-04 2011-04-13 Farmalider S.A. Composicion farmaceutica de ibuprofeno, tramadol y un aminoacido basico, procedimiento para su preparacion y utilizacion de la misma.
CN102058581A (zh) * 2010-11-30 2011-05-18 广东宏盈科技有限公司 一种眼科外用非甾体抗炎药
WO2013124498A1 (es) * 2012-02-22 2013-08-29 Farmauder, S.A. Composición farmacéutica de ibuprofeno y tramadol para inyección
WO2013150277A1 (en) * 2012-04-05 2013-10-10 Anant Sharma Ophthalmic therapy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2604816A1 (es) * 2015-09-09 2017-03-09 Farmalider, S.A. Composición farmacéutica de tramadol para uso oftálmico
WO2017042404A1 (es) * 2015-09-09 2017-03-16 Farmalider, S.A. Composición farmacéutica de tramadol para uso oftálmico

Also Published As

Publication number Publication date
DK2862565T3 (en) 2018-08-13
ES2685023T3 (es) 2018-10-05
US10292953B2 (en) 2019-05-21
US20150105468A1 (en) 2015-04-16
BR102014025307A2 (pt) 2015-09-29
MX2014012158A (es) 2015-05-27
MX355770B (es) 2018-04-30
RU2014140885A3 (es) 2018-06-14
PT2862565T (pt) 2018-10-16
AR097997A1 (es) 2016-04-27
EP2862565A1 (en) 2015-04-22
EP2862565B1 (en) 2018-05-23
RU2014140885A (ru) 2016-04-27
CY1120642T1 (el) 2019-12-11
HUE040093T2 (hu) 2019-02-28
ES2540151B1 (es) 2016-02-29
BR102014025307B1 (pt) 2021-11-03
HRP20181282T1 (hr) 2018-10-05
RU2694369C2 (ru) 2019-07-12
PL2862565T3 (pl) 2018-10-31

Similar Documents

Publication Publication Date Title
ES2540151A1 (es) Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CL2017002527A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares. (divisional de solicitud n°2485-2015).
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
BR112015020804A2 (pt) dispositivo fototerapeutico, método e uso
EA201800064A1 (ru) 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl
EA201690212A1 (ru) Способы лечения или профилактики офтальмологических патологических состояний
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112015004875A2 (pt) formulações de anticorpo e seus usos
GT201600084A (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112015011898A2 (pt) forma cristalina a da chidamida, método para preparar a forma cristalina a da chidamida, uso da forma cristalina a da chidamida, forma cristalina b da chidamida, método para preparar a forma cristalina b da chidamida, uso da forma cristalina b da chidamida e formulação farmacêutica para o tratamento de doenças relacionadas à diferenciação e proliferação celular
WO2016057658A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
BR112015021265A2 (pt) métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112019002355A2 (pt) composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme
EA201792056A1 (ru) Лечение пациентов с сахарным диабетом 2 типа
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
BR112015017381A2 (pt) agentes analgésicos oculares tópicos
EA201690574A1 (ru) Применение пидотимода в лечении заболеваний, связанных с воспалением

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2540151

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160229